Author： Elming Hanne Brendorp Bente Pehrson Steen Pedersen Ole Dyg Køber Lars Torp-Petersen Christian
Publisher： Informa Healthcare
ISSN： 1474-0338
Source： Expert Opinion on Drug Safety, Vol.3, Iss.6, 2004-11, pp. : 559-577
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A Benefit-Risk Assessment of Class III Antiarrhythmic Agents
By Brendorp B.
Drug Safety, Vol. 25, Iss. 12, 2002-01 ,pp. :
Access to resources
Recommend
A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke
By MacWalter R.S. Shirley C.P.
Drug Safety, Vol. 25, Iss. 13, 2002-01 ,pp. :
Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer
Drug Safety, Vol. 28, Iss. 5, 2005-01 ,pp. :
A Preliminary Benefit-Risk Assessment of Varenicline in Smoking Cessation
By Cahill Kate Stead Lindsay Lancaster Tim
Drug Safety, Vol. 32, Iss. 2, 2009-01 ,pp. :
Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia
Drug Safety, Vol. 26, Iss. 9, 2003-01 ,pp. :